ProKidney Corp.
NASDAQ:PROK · NASDAQ Capital Market
+$0.02 today
Vol 0.56M · Avg 0.96M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PROK · Revenue to Net Income
Key Ratios
Analysis
$889.0K of revenue converted into -$74.8M of net income for the selected period. Gross margin is -219.7% and net margin is -8404.8%, showing how much revenue survives after costs and taxes. EPS is $-0.55, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $893.0K +1075.0% | $76.0K | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $893.0K +1075.0% | $76.0K | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +0.0pp | 100.0% | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $114.1M -10.6% | $127.7M +19.6% | $106.7M +30.0% | $82.1M +77.4% | $46.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $51.8M -7.7% | $56.1M +25.1% | $44.8M -36.8% | $70.9M +701.1% | $8.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $165.9M -9.7% | $183.8M +21.3% | $151.5M -1.0% | $153.0M +177.6% | $55.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $6.6M +21.0% | $5.4M +41.0% | $3.9M +26.9% | $3.0M +53.0% | $2.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$144.6M +8.8% | -$158.5M -26.2% | -$125.6M +12.8% | -$144.0M -171.0% | -$53.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -16194.7% +192347.4pp | -208542.1% | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$165.0M +10.2% | -$183.7M -21.2% | -$151.5M +1.0% | -$153.0M -177.6% | -$55.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -18477.8% +223201.1pp | -241678.9% | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $13.8M -30.1% | $19.8M -10.6% | $22.1M +269.1% | $6.0M +299050.0% | $2.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $4.0K -55.6% | $9.0K -25.0% | $12.0K -94.4% | $215.0K | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $13.8M -30.1% | $19.7M -10.5% | $22.1M +282.6% | $5.8M +288300.0% | $2.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$151.2M +7.8% | -$163.9M -26.6% | -$129.5M +12.1% | -$147.2M -167.2% | -$55.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -16931.5% +198769.8pp | -215701.3% | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $414.0K +169.2% | -$598.0K -110.0% | $6.0M +569.2% | $896.0K +2257.9% | $38.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$69.0M -12.7% | -$61.2M -72.5% | -$35.5M +67.2% | -$108.0M -95.9% | -$55.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -7725.2% +72782.7pp | -80507.9% | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +16.1% | -$1 -8.8% | -$1 +67.6% | -$2 -1.7% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +16.1% | -$1 -8.8% | -$1 +67.6% | -$2 -1.7% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $133.9M +36.8% | $97.9M +58.7% | $61.7M +0.3% | $61.5M +93.0% | $31.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $133.9M +36.8% | $97.9M +58.7% | $61.7M +0.3% | $61.5M +93.0% | $31.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector

Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.53B

Nanobiotix S.A.
NASDAQ:NBTX
$1.81B

Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.68B
Septerna, Inc.
NASDAQ:SEPN
$1.59B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.27B

EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B

Savara Inc.
NASDAQ:SVRA
$1.12B

Kura Oncology, Inc.
NASDAQ:KURA
$858.00M

Prime Medicine, Inc.
NASDAQ:PRME
$568.04M

Rezolute, Inc.
NASDAQ:RZLT
$488.68M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PROK generate?
ProKidney Corp. (PROK) reported $893,000.00 of revenue in fiscal 2025.
Is PROK profitable?
ProKidney Corp. (PROK) reported -$68,986,000.00 of net income, with a net margin of -7725.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.